JP6510544B2 - ウコンならびにホソババレンギクの抽出物を含有する、末梢性炎症ならびに疼痛の軽減に有用な組成物 - Google Patents
ウコンならびにホソババレンギクの抽出物を含有する、末梢性炎症ならびに疼痛の軽減に有用な組成物 Download PDFInfo
- Publication number
- JP6510544B2 JP6510544B2 JP2016552578A JP2016552578A JP6510544B2 JP 6510544 B2 JP6510544 B2 JP 6510544B2 JP 2016552578 A JP2016552578 A JP 2016552578A JP 2016552578 A JP2016552578 A JP 2016552578A JP 6510544 B2 JP6510544 B2 JP 6510544B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- composition
- well
- osteoarthritis
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims description 43
- 239000000203 mixture Substances 0.000 title claims description 37
- 208000002193 Pain Diseases 0.000 title description 15
- 235000003392 Curcuma domestica Nutrition 0.000 title description 4
- 235000003373 curcuma longa Nutrition 0.000 title description 4
- 230000002093 peripheral effect Effects 0.000 title description 4
- 235000013976 turmeric Nutrition 0.000 title description 4
- 244000008991 Curcuma longa Species 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 48
- 239000004148 curcumin Substances 0.000 claims description 22
- 235000012754 curcumin Nutrition 0.000 claims description 22
- 229940109262 curcumin Drugs 0.000 claims description 22
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 22
- 150000003904 phospholipids Chemical class 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 201000008482 osteoarthritis Diseases 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- KDSNLYIMUZNERS-UHFFFAOYSA-N 2-methylpropanamine Chemical compound CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 12
- 241000269333 Caudata Species 0.000 description 7
- 244000163122 Curcuma domestica Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 235000014375 Curcuma Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 244000133098 Echinacea angustifolia Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000012675 alcoholic extract Substances 0.000 description 3
- 235000014134 echinacea Nutrition 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000157282 Aesculus Species 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 244000089698 Zanthoxylum simulans Species 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 241000256111 Aedes <genus> Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 241000207892 Convolvulus Species 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 240000002878 Prunus cerasus Species 0.000 description 1
- 235000005805 Prunus cerasus Nutrition 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical class O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- -1 many polyphenols Chemical compound 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
ウコン属の抽出物、または、クルクミン;および
ホソババレンギク(Echinacea angustifolia)の抽出物またはカホクザンショウ(Zanthoxylum bungeanum)の親油性抽出物から選択される抽出物とからなる、組成物である。
ウコン属の抽出物、または、クルクミン;および
ホソババレンギク(Echinacea angustifolia)の抽出物またはカホクザンショウ(Zanthoxylum bungeanum)の親油性抽出物から選択される抽出物とからなる、組成物に関する。
リン脂質と複合体化された、クルクミンを、100〜1000mgの範囲の量、および
ムラサキバレンギク属の抽出物を、1〜20mgの範囲の量、
あるいは、サンショウ属の親油性抽出物を、5〜25mgの範囲の量を含有することができる。特に好ましい形態においては、経口投与用の組成物は、経口単位投与量当たり、
リン脂質と複合体化された、クルクミンを500mg、および
ムラサキバレンギク属の抽出物を5mg、
あるいは、サンショウ属の親油性抽出物を10mg、含有することができる。
リン脂質と複合体化された、クルクミンを、0.1〜0.5質量%の範囲の量、および
ムラサキバレンギク属の抽出物を、0.05〜0.5質量%の範囲の量、
あるいは、サンショウ属の親油性抽出物を、0.1〜1質量%の範囲の量で含有することができる。特に好ましい形態においては、局所投与用の組成物は、
リン脂質と複合体化された、クルクミンを0.2質量%、および
ムラサキバレンギク属の抽出物を0.2質量%、
あるいは、サンショウ属の親油性抽出物を0.5質量、含有することができる。
薬理学的試験
1.ラットにおける、Tail−flickテスト
本発明にかかる組成物(リン脂質と複合体化された、クルクミンとムラサキバレンギク属の抽出物の組み合わせ)の鎮痛活性を、ラットに対して、個々の成分を個別的に投与した際の活性と比較した。下記の表1に示される通り、結果は、本発明にかかる組成物の該二つの成分の間における、明確な相乗効果を査証した。
持続的な痛みを伴う、ひざの骨疾患を患っている患者40名を、無作為に割り付け、そして、朝1錠ならびに夕方1錠、例1にかかる錠剤を1日2錠、あるいは、(媒体のみぁからなる)プラセボ、プラセボの処方に、例1に記載される処方中と同じ濃度で加えられた、個々の成分により、治療を行った。
表3は、本発明にかかる組成物による、3か月に達する治療後、変形性骨関節炎への全体的な効果について、選別ならびに有効性の評価について、Kamonfsky スケール(J. Clin. Oncology, 1984; 2:187-193)に従って、募集に応じた患者において得られた結果を示す。
例1 :リン脂質と複合体化された、クルクミン、ならびに、ムラサキバレンギク属の親油性抽出物を含有する錠剤
Claims (8)
- 許容される賦形剤と混合された、実質的に、
リン脂質と複合体化された、クルクミン;および
ホソババレンギクの抽出物とからなる、変形性骨関節炎ならびにリウマチ性関節炎の治療用途の、組成物。 - ホソババレンギクの抽出物は、超臨界二酸化炭素による抽出により調製されている
ことを特徴とする、請求項1に記載の組成物。 - 経口投与用である、請求項1又は2に記載の組成物。
- 経口投与用であり、
経口単位投与量当たり、
リン脂質と複合体化された、クルクミンを、100〜1000mgの範囲の量、および
ホソババレンギクの抽出物を、1〜20mgの範囲の量を、
それらの活性成分としてのみ、含有している
ことを特徴とする、変形性骨関節炎ならびにリウマチ性関節炎の治療用途の、組成物。 - 経口単位投与量当たり、
リン脂質と複合体化された、クルクミンを500mg、および
ホソババレンギクの抽出物を5mg、
それらの活性成分としてのみ、含有している
ことを特徴とする、請求項4に記載の組成物。 - 局所投与用である、請求項1又は2に記載の組成物。
- 局所投与用であり、
リン脂質と複合体化された、クルクミンを、0.1%〜0.5%w/wの範囲の量、および
ホソババレンギクの抽出物を、0.05%〜0.5%w/wの範囲の量で、
含有している
ことを特徴とする、変形性骨関節炎ならびにリウマチ性関節炎の治療用途の、組成物。 - リン脂質と複合体化された、クルクミンを0.2%w/w、および
ホソババレンギクの抽出物を0.2%w/w、
含有している
ことを特徴とする、請求項7に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI20140251 | 2014-02-20 | ||
ITMI2014A000251 | 2014-02-20 | ||
PCT/EP2015/053399 WO2015124616A1 (en) | 2014-02-20 | 2015-02-18 | Compositions containing extracts of curcuma longa and echinacea angustifolia which are useful to reduce peripheral inflammation and pain |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017506241A JP2017506241A (ja) | 2017-03-02 |
JP6510544B2 true JP6510544B2 (ja) | 2019-05-08 |
Family
ID=50336467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016552578A Active JP6510544B2 (ja) | 2014-02-20 | 2015-02-18 | ウコンならびにホソババレンギクの抽出物を含有する、末梢性炎症ならびに疼痛の軽減に有用な組成物 |
Country Status (19)
Country | Link |
---|---|
US (1) | US10286028B2 (ja) |
EP (1) | EP3107555B1 (ja) |
JP (1) | JP6510544B2 (ja) |
KR (1) | KR102350519B1 (ja) |
CN (1) | CN106029082A (ja) |
AU (1) | AU2015220913B2 (ja) |
BR (1) | BR112016018973B1 (ja) |
CA (1) | CA2939976C (ja) |
DK (1) | DK3107555T3 (ja) |
ES (1) | ES2804324T3 (ja) |
HU (1) | HUE051696T2 (ja) |
IL (1) | IL247314B (ja) |
MX (1) | MX2016010722A (ja) |
PL (1) | PL3107555T3 (ja) |
PT (1) | PT3107555T (ja) |
RU (1) | RU2677894C2 (ja) |
SG (1) | SG11201606831PA (ja) |
SI (1) | SI3107555T1 (ja) |
WO (1) | WO2015124616A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3150214A1 (en) * | 2015-10-01 | 2017-04-05 | INDENA S.p.A. | Compositions containing extracts of curcuma spp and zingiber officinale which are useful to reduce peripheral inflammation and pain |
EP3389644B1 (en) | 2015-12-16 | 2022-01-26 | Parachur, Vivek Anand | Tri-molecular complex of natural compounds |
ITUB20161030A1 (it) * | 2016-02-24 | 2017-08-24 | Indena Spa | Composizioni utili nella prevenzione e/o nel trattamento dell’infiammazione e del dolore |
US10744174B1 (en) * | 2016-03-16 | 2020-08-18 | Robert Alonso | Composition(s) and method(s) for topically treating pain |
ITUA20164757A1 (it) | 2016-06-29 | 2017-12-29 | Indena Spa | Composizioni utili nella prevenzione e/o nel trattamento dell’infiammazione e del dolore osteoarticolare e del danno cartilagineo |
JP6987528B2 (ja) * | 2017-05-12 | 2022-01-05 | 小林製薬株式会社 | クルクミノイド含有錠剤 |
KR102020667B1 (ko) * | 2017-09-29 | 2019-09-10 | 유씨엘 주식회사 | 두피염증 예방 및 완화, 및 탈모방지 효과가 있는 화장료 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2075187T3 (es) * | 1990-07-05 | 1995-10-01 | Indena Spa | Extractos de equinaceas, un procedimiento para su preparacion y formulaciones que los contienen. |
US6440448B1 (en) * | 1998-03-16 | 2002-08-27 | Joseph Intelisano | Food supplement/herbal composition for health enhancement |
ITMI981542A1 (it) * | 1998-07-07 | 2000-01-07 | Indena Spa | Estratti di zanthoxylum bungeanum e loro formulazioni farmaceutiche e cosmetiche |
JP5032003B2 (ja) * | 2005-06-15 | 2012-09-26 | 株式会社琉球バイオリソース開発 | 口腔粘膜用の鎮痛・抗炎症トローチ剤 |
EP1837030A1 (en) * | 2006-03-09 | 2007-09-26 | INDENA S.p.A. | Phospholipid complexes of curcumin having improved bioavailability |
ITMI20071136A1 (it) * | 2007-06-04 | 2008-12-05 | Velleja Res Srl | Formulazioni topiche per la prevenzione e il trattamento degli stati infiammatori e/o infettivi dell'aera genitale |
KR20090047637A (ko) * | 2007-11-08 | 2009-05-13 | 재단법인서울대학교산학협력재단 | 커큐민 또는 이의 약학적으로 허용가능한 염을유효성분으로 함유하는 통증 예방 및 치료용 조성물 |
CN101607068A (zh) | 2009-07-15 | 2009-12-23 | 中国人民解放军第四军医大学 | 一种治疗肝癌中药前体脂质体注射剂及其制备工艺 |
IT1401141B1 (it) * | 2010-07-26 | 2013-07-12 | Indena Spa | Formulazioni contenenti estratti di echinacea angustifolia e di zingiber officinale utili nella riduzione dell'infiammazione e del dolore periferico |
-
2015
- 2015-02-18 JP JP2016552578A patent/JP6510544B2/ja active Active
- 2015-02-18 ES ES15709426T patent/ES2804324T3/es active Active
- 2015-02-18 MX MX2016010722A patent/MX2016010722A/es active IP Right Grant
- 2015-02-18 BR BR112016018973-6A patent/BR112016018973B1/pt active IP Right Grant
- 2015-02-18 CA CA2939976A patent/CA2939976C/en active Active
- 2015-02-18 SI SI201531247T patent/SI3107555T1/sl unknown
- 2015-02-18 DK DK15709426.9T patent/DK3107555T3/da active
- 2015-02-18 WO PCT/EP2015/053399 patent/WO2015124616A1/en active Application Filing
- 2015-02-18 RU RU2016133688A patent/RU2677894C2/ru active
- 2015-02-18 SG SG11201606831PA patent/SG11201606831PA/en unknown
- 2015-02-18 US US15/118,861 patent/US10286028B2/en active Active
- 2015-02-18 PL PL15709426T patent/PL3107555T3/pl unknown
- 2015-02-18 HU HUE15709426A patent/HUE051696T2/hu unknown
- 2015-02-18 PT PT157094269T patent/PT3107555T/pt unknown
- 2015-02-18 KR KR1020167022484A patent/KR102350519B1/ko active IP Right Grant
- 2015-02-18 AU AU2015220913A patent/AU2015220913B2/en active Active
- 2015-02-18 CN CN201580009045.8A patent/CN106029082A/zh active Pending
- 2015-02-18 EP EP15709426.9A patent/EP3107555B1/en active Active
-
2016
- 2016-08-17 IL IL247314A patent/IL247314B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
PT3107555T (pt) | 2020-07-10 |
AU2015220913B2 (en) | 2020-04-09 |
BR112016018973B1 (pt) | 2021-01-19 |
KR20160113631A (ko) | 2016-09-30 |
JP2017506241A (ja) | 2017-03-02 |
US10286028B2 (en) | 2019-05-14 |
CA2939976A1 (en) | 2015-08-27 |
US20170049840A1 (en) | 2017-02-23 |
AU2015220913A1 (en) | 2016-09-01 |
IL247314A0 (en) | 2016-09-29 |
CN106029082A (zh) | 2016-10-12 |
RU2016133688A3 (ja) | 2018-08-30 |
KR102350519B1 (ko) | 2022-01-14 |
RU2677894C2 (ru) | 2019-01-22 |
PL3107555T3 (pl) | 2020-11-30 |
EP3107555B1 (en) | 2020-06-03 |
CA2939976C (en) | 2023-09-05 |
WO2015124616A1 (en) | 2015-08-27 |
MX2016010722A (es) | 2016-11-10 |
IL247314B (en) | 2020-08-31 |
DK3107555T3 (da) | 2020-08-10 |
EP3107555A1 (en) | 2016-12-28 |
RU2016133688A (ru) | 2018-03-23 |
SI3107555T1 (sl) | 2020-07-31 |
HUE051696T2 (hu) | 2021-03-29 |
SG11201606831PA (en) | 2016-09-29 |
ES2804324T3 (es) | 2021-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6510544B2 (ja) | ウコンならびにホソババレンギクの抽出物を含有する、末梢性炎症ならびに疼痛の軽減に有用な組成物 | |
Imo et al. | Effects of ethanolic extracts of leaf, seed and fruit of Datura metel L. on kidney function of male albino rats | |
WO2011045732A2 (en) | A composition with enhanced thermogenic activity and the use thereof in the prevention and treatment of obesity | |
Alkandahri et al. | Evaluation of antioxidant and antipyretic effects of ethanolic extract of cep-cepan leaves (Castanopsis costata (Blume) A. DC) | |
JP2019520368A (ja) | 骨関節の炎症および疼痛ならびに軟骨損傷の予防および/または治療に有用な組成物 | |
EP3009013A1 (en) | Therapeutic and nutritional compositions for functional gastrointestinal disorders | |
ES2939366T3 (es) | Formulaciones que contienen extractos lipófilos de plantas comestibles especiadas útiles para controlar el dolor y la inflamación | |
Hu et al. | Acute oral toxicity test and assessment of rhynchophylline in mice. | |
RU2240131C1 (ru) | Средство "артровит" для профилактики и лечения артритов и артрозов | |
WO2017055481A1 (en) | Compositions containing extracts of curcuma spp and zingiber officinale which are useful to reduce peripheral inflammation and pain | |
JP7111617B2 (ja) | 炎症および疼痛の予防および/または治療において有用な組成物 | |
Audrey et al. | Evaluation of the anti-inflammatory activity of a gel based on Afzelia africana (fabaceae) leaves | |
Baby et al. | Review on Gandhaka Druti: An Unexplored Herbo-mineral Formulation | |
Fikayuniar et al. | Evaluation of antioxidant and antipyretic effects of ethanolic extract of Cep-cepan leaves (Castanopsis costata (Blume) A. DC) | |
Dixit | MEDICINAL IMPORTANCE OF PLANTS: AN OVERVIEW |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181009 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190109 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190122 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190314 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190326 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190404 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6510544 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |